ChromaDex Corporation Aktie News

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces an ingredient partnership with Solgar®, a Nestlé Health Science brand. Solgar's inaugural NAD+ supplement, Solgar Cellular Nutrition Cellular Energy, features ChromaDex's patented nicotinamide riboside (NR) ...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship consumer supplement, Tru Niagen®, is now available at The Vitamin Shoppe retail locations nationwide and online at www.vitaminshoppe.com. This retail expansion adds Tru Niagen to the shelve...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024. The financial results will be reported in a press ...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Sprouts Farmers Market, marking its inaugural major grocery debut. As one of the fas...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs, a leading third-party testing laboratory known for its rigo...

ChromaDex Corporation (NASDAQ:CDXC ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - CEO Brianna Gerber - CFO Andrew Shao - Senior Vice President of Scientific and Regulatory Affairs Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Mitchell Pinheiro - Sturdivant & Company Sean McGowan - ROTH MKM...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Total net sales of $21.2 million, with $17.6 million from Tru Niagen®, up 1% and 9%, respectively, from the prior year quarter. Delivered strong gross margin of 61.0%, an increase of 380 basis points, co...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after t...